Genetic variants to predict Semaglutide (Ozempic) weight loss, glucose, and adverse event response

Glucagon-like peptide 1 (GLP-1) receptor agonists, including semaglutide and tirzepatide, have transformed the clinical management of overweight and obesity, and Type 2 Diabetes Mellitus (T2DM). Despite their significant efficacy, substantial inter-person variability exists in both the magnitude of weight loss achieved and the incidence of common gastrointestinal side effects. This variability presents a significant challenge, as clinicians currently lack tools to predict which patients will respond optimally or experience adverse events. Identifying specific genetic variants associated with these differential responses could pave the way for personalized medicine strategies, optimizing treatment selection and improving patient outcomes.

This retrospective study aims to assess whether specific genetic variants can identify individuals who will have a satisfactory response to GLP-1 treatment. Participants will undergo a single visit at a diabetes unit clinic. Data collection includes informed consent, eligibility screening, demographic information (age, gender, ethnic origin), general and T2DM medical history, and concomitant medication review. Physical attributes such as Body Weight, Height, and BMI will be recorded. Crucially, saliva and blood samples will be collected for genetic testing. Participants will also complete a self-reported questionnaire detailing their experience with Ozempic (Semaglutide), covering efficacy and adverse events.

Written by TitrateLab, separately from the study summarized above.